Company

Nusano, Inc.

Nusano develops radioisotopes for diagnostic imaging and cancer treatments.

About

Nusano develops medical-grade radioisotopes for diagnostic and therapeutic applications in cancer care. Its particle beam technology produces isotopes for imaging, pharmaceuticals and cancer therapies. Founded in 2013 by Glenn Rosenthal and Howard Lewin, it is based in Valencia, California, and is at Series C stage. In October 2024, it raised USD 115 million from Wasatch Equity Partners, BrightEdge Ventures, Section 32 and Verily Life Sciences LLC to support the launch of lutetium-177 (n.c.a. Lu-177) and actinium-225 (Ac-225).

3Funding rounds

3Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in